Cwm LLC Decreases Holdings in CRISPR Therapeutics AG $CRSP

Cwm LLC cut its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 38.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,341 shares of the company’s stock after selling 1,462 shares during the quarter. Cwm LLC’s holdings in CRISPR Therapeutics were worth $114,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. SVB Wealth LLC purchased a new stake in CRISPR Therapeutics during the 1st quarter valued at $25,000. Costello Asset Management INC purchased a new stake in CRISPR Therapeutics during the 1st quarter valued at $27,000. Quantbot Technologies LP boosted its position in CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock valued at $45,000 after buying an additional 978 shares during the period. IFP Advisors Inc boosted its position in CRISPR Therapeutics by 24.6% during the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after buying an additional 181 shares during the period. Finally, GF Fund Management CO. LTD. boosted its position in CRISPR Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company’s stock valued at $74,000 after buying an additional 394 shares during the period. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the completion of the transaction, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at $17,262,789.91. This trade represents a 16.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 56,213 shares of company stock valued at $3,810,458. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of CRISPR Therapeutics in a research report on Thursday, September 18th. They set an “overweight” rating and a $70.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $81.00 price target on shares of CRISPR Therapeutics in a research report on Friday, October 10th. Royal Bank Of Canada increased their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a research report on Tuesday, August 5th. Bank of America lifted their price target on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a report on Friday, October 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Ten research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $72.59.

CRISPR Therapeutics Stock Up 4.7%

NASDAQ:CRSP opened at $63.99 on Friday. The stock has a market cap of $5.82 billion, a P/E ratio of -11.78 and a beta of 1.84. The firm’s fifty day simple moving average is $62.53 and its 200 day simple moving average is $52.35. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The company’s revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.49) EPS. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.